MedElevator Войти в исследования
← Поиск публикаций
Медицинская библиотека · Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2015

Profiles and clinical management of hepatitis C patients in Spain: disHCovery study.

Buti Maria, Franco Alejandro, Carmona Isabel, Sánchez-Ruano Juan Jose, Sansó Andreu, Berenguer Marina, García-Buey Luisa, Hernández-Guerra Manuel, Morillas Rosa Maria, Ledesma Francisco, Esteban Rafael, disHCovery Study Group

СтатьяМногоцентровое исследованиеНаблюдательное исследованиеПеревод пока не подготовлен

Аннотация

INTRODUCTION

To assess the clinical profile and management of patients with hepatitis C (HCV) infection in an observational study in Spanish hospitals.

METHODS

The study included an initial cross-sectional phase (study phase I), in which investigators at 48 hospitals from 14 Spanish regions collected data from approximately 20 consecutive patients each (a total of 1,000 patients) to assess the general features of HCV-infected patients of any genotype. During the second phase (study phase II), data from 878 patients that were infected exclusively with genotype 1 HCV were assessed retrospectively. Eight pre-defined clinical profiles were established, in order to assess clinical and previous treatments characteristics.

RESULTS

Among the HCV-infected individuals that were analysed during the first part, HCV genotype 1 was found to be predominant (with a prevalence of 76.6%), prevailing the subtype 1b (69.8%), with other significant groups infected by genotype 3 (12.3%) and 4 (7.4%). In the second part of the study, 44% of the HCV genotype 1-infected patients were at a F3/F4 fibrosis stage. 15.9% had never been treated, and previously unsuccessfully treated patients that were no longer receiving anti-HCV treatment accounted for 50.8% of cases. Individuals with a sustained virologic response (SVR) to previous dual therapies (based on Interferon and Ribavirin) were only 14.5% and patients under treatment during the study accounted for the remaining 18.8%. A total of 713 patients (81.2%) in the second phase were not receiving any type of therapy over the period analysed, mainly due to the anticipation of new anti-HCV drugs (41.8%), SVR achievement (17.8%) and unresponsiveness to therapies available at the time of the study (9.5%).

CONCLUSIONS

HCV genotype 1, predominately 1b, is the most prevalent type in Spain. Advanced fibrosis or cirrhosis is frequent in this group, mainly patients not yet cured.

Для цитирования: Buti Maria, Franco Alejandro, Carmona Isabel, Sánchez-Ruano Juan Jose, Sansó Andreu, Berenguer Marina, García-Buey Luisa, Hernández-Guerra Manuel, Morillas Rosa Maria, Ledesma Francisco, Esteban Rafael, disHCovery Study Group. Profiles and clinical management of hepatitis C patients in Spain: disHCovery study.. Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia. 2015.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.